Stoke Therapeutics Q3 2023 net loss $24.5M; cash $214.7M funds into 2025

Stoke Therapeutics, Inc.

2023-Q3 EPS reported -$1.78 revenue$5,978,000

Net loss of $24.5M ($0.55 per share) vs $26.1M ($0.66) in Q3 2022.
Revenue of $3.3M from Acadia license/services; cash runway to end of 2025.
STK-001 Phase 1/2a results plus OLE data expected Q1 2024; then regulatory meeting for Phase 3 design.
STK-002 Phase 1 study (OSPREY) for ADOA to start in UK early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Stoke Therapeutics, Inc. reported three months ended September 30, 2023 results: revenue $3.3 million, net income -$24.5 million, EPS -$0.55 per share.

Period: three months ended September 30, 2023
Revenue: $3.3 million
Net income: -$24.5 million
EPS: -$0.55 per share
Result: reported results

Exact text from the filing

Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the three months ended September 30, 2023, was $3.3 million, compared to $2.9 million for the same period in 2022. • Net loss for the three months ended September 30, 2023, was $24.5 million, or $0.55 per share, compared to $26.1 million, or $0.66 per share, for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-059756

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.